Patents by Inventor Steven Carl Chatlton

Steven Carl Chatlton has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • IP receptor agonist heterocyclic compounds
    Publication number: 20150005311
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: January 1, 2015
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl Mckeown
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140357641
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor, processes for preparing them, pharmaceutical compositions comprising said derivatives and uses thereof. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Gurdip Bhalay, Steven Carl Chatlton, Mark Patrick Healy, Catherine Leblanc, Stephen Carl McKeown
  • IP receptor agonist heterocyclic compounds
    Publication number: 20140357642
    Abstract: The present invention provides heterocyclic derivatives which activate the IP receptor. Activating the IP receptor signaling pathway is useful to treat many forms of PAH, pulmonary fibrosis and exert beneficial effects in fibrotic conditions of various organs in animal models and in patients. Pharmaceutical compositions comprising such derivatives are also encompassed.
    Type: Application
    Filed: January 11, 2013
    Publication date: December 4, 2014
    Applicant: NOVARTIS AG
    Inventors: Steven Carl Chatlton, Catherine Leblanc, Stephen Carl McKeown